BACKGROUND: This study compared long-term survival in pancreatic or periampullary cancer treated with Whipple pancreatoduodenectomy (PD) and pylorus-preserving pancreatoduodenectomy (PPPD). METHODS: Two hundred twenty-one patients with pancreatic head or periampullary cancer were treated. Prognostic variables included age, gender, type and period of operation, and tumor stage. In the ductal adenocarcinomas variables also included tumor and node status, type of lymphadenectomy, pathologic grade, and presence of microscopic residual tumor. The end point was death as a result of neoplastic recurrence. Survival curves were estimated by using the Kaplan-Meier method, and multifactorial analysis was also performed on the data from the ductal adenocarcinoma group. RESULTS: The mortality rate was 8.2% in the PD group versus 7.0% in the PPPD group. Morbidity rates were 34.4% for PD and 45.8% for PPPD. Five-year survival was 9.6% in the ductal adenocarcinoma and 63.8% in the periampullary carcinoma groups. Univariate analysis failed to show statistically significant differences in survival curves between the two treatments in either patient group. Correcting for multiple variables in the ductal adenocarcinoma group did not reveal any significant differences in survival rates between the two treatments. CONCLUSIONS: PPPD was as successful as classic PD in the treatment of ductal adenocarcinoma and periampullary cancer of the pancreas. Long-term survival was not influenced by the type of resection.
BACKGROUND: This study compared long-term survival in pancreatic or periampullary cancer treated with Whipple pancreatoduodenectomy (PD) and pylorus-preserving pancreatoduodenectomy (PPPD). METHODS: Two hundred twenty-one patients with pancreatic head or periampullary cancer were treated. Prognostic variables included age, gender, type and period of operation, and tumor stage. In the ductal adenocarcinomas variables also included tumor and node status, type of lymphadenectomy, pathologic grade, and presence of microscopic residual tumor. The end point was death as a result of neoplastic recurrence. Survival curves were estimated by using the Kaplan-Meier method, and multifactorial analysis was also performed on the data from the ductal adenocarcinoma group. RESULTS: The mortality rate was 8.2% in the PD group versus 7.0% in the PPPD group. Morbidity rates were 34.4% for PD and 45.8% for PPPD. Five-year survival was 9.6% in the ductal adenocarcinoma and 63.8% in the periampullary carcinoma groups. Univariate analysis failed to show statistically significant differences in survival curves between the two treatments in either patient group. Correcting for multiple variables in the ductal adenocarcinoma group did not reveal any significant differences in survival rates between the two treatments. CONCLUSIONS:PPPD was as successful as classic PD in the treatment of ductal adenocarcinoma and periampullary cancer of the pancreas. Long-term survival was not influenced by the type of resection.
Authors: Dean Bogoevski; Emre F Yekebas; Paulus Schurr; Jussuf T Kaifi; Asad Kutup; Andreas Erbersdobler; Klaus Pantel; Jakob R Izbicki Journal: Ann Surg Date: 2004-12 Impact factor: 12.969
Authors: Markus K Diener; Hanns-Peter Knaebel; Christina Heukaufer; Gerd Antes; Markus W Büchler; Christoph M Seiler Journal: Ann Surg Date: 2007-02 Impact factor: 12.969
Authors: Jörg Köninger; Moritz N Wente; Michael W Müller; Carsten N Gutt; Helmut Friess; Markus W Büchler Journal: Langenbecks Arch Surg Date: 2006-11-11 Impact factor: 3.445
Authors: M Schenck; F vom Dorp; C Boergermann; Y Busch; A Carpinteiro; B Wilker; S Keitsch; K W Schmid; M Groneberg; M Stuschke; H Ruebben; E Gulbins Journal: Urologe A Date: 2007-09 Impact factor: 0.639
Authors: Jeannine Bachmann; Christoph W Michalski; Marc E Martignoni; Markus W Büchler; Helmut Friess Journal: HPB (Oxford) Date: 2006 Impact factor: 3.647
Authors: Emre-F Yekebas; Dean Bogoevski; Michael Bubenheim; Björn-Christian Link; Jussuf-T Kaifi; Robin Wachowiak; Oliver Mann; Asad Kutup; Guellue Cataldegirmen; Lars Wolfram; Andreas Erbersdobler; Christoph Klein; Klaus Pantel; Jakob-R Izbicki Journal: World J Gastroenterol Date: 2006-10-28 Impact factor: 5.742